BC
DAWN

Boxer Capital’s Day One Biopharmaceuticals DAWN Stock Holding History

Boxer Capital’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,189,943
Closed -$16.6M – 12
2024
Q3 		$16.6M Hold
1,189,943
– – 0.81% 36
2024
Q2 		$16.4M Hold
1,189,943
– – 0.86% 30
2024
Q1 		$19.7M Hold
1,189,943
– – 0.97% 30
2023
Q4 		$17.4M Hold
1,189,943
– – 0.87% 29
2023
Q3 		$14.6M Hold
1,189,943
– – 0.78% 39
2023
Q2 		$14.2M Hold
1,189,943
– – 0.66% 41
2023
Q1 		$15.9M Hold
1,189,943
– – 0.78% 37
2022
Q4 		$25.6M Hold
1,189,943
– – 1.35% 28
2022
Q3 		$23.8M Hold
1,189,943
– – 1.34% 26
2022
Q2 		$21.3M Hold
1,189,943
– – 1.35% 27
2022
Q1 		$11.8M Hold
1,189,943
– – 0.61% 39
2021
Q4 		$20.1M Hold
1,189,943
– – 0.78% 31
2021
Q3 		$28.2M Hold
1,189,943
– – 0.99% 28
2021
Q2 		$27.1M Buy
+1,189,943
New +$24.8M 0.96% 29

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ECM
Estuary Capital Management Wayzata, Minnesota $598M AUM 1.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Boxer Capital's DAWN Position: Q4 2024 in Review

Boxer Capital sold out of Day One Biopharmaceuticals (DAWN) in Q4 2024, closing a stake of 1,189,943 shares — an estimated $16.6M sold.

Boxer Capital first reported a position in DAWN in Q2 2021 and held it in 14 quarters. The position peaked at $28.2M in Q3 2021. 164 funds tracked by Wall St. Rank hold DAWN as of Q4 2024.

  • Boxer Capital reported no remaining Day One Biopharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Boxer Capital sold 1,189,943 Day One Biopharmaceuticals shares in Q4 2024, an estimated $16.6M.
  • Boxer Capital first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 14 quarters.
  • Boxer Capital's Day One Biopharmaceuticals position peaked at $28.2M in Q3 2021.
  • 164 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.